MAINZ BIOMED N.V.
Ticker(s):
MYNZ
Country:
Sector & Industry:
Business Overview
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product. The company was founded in 2008 and is based in Mainz, Germany.
Contact & Other Information
Number of Employees:
65
Website:
Robert Koch Strasse 50
Mainz
,
,
55129
Germany
49 6131 554 2860
No content was found.